Biological and Pharmaceutical Bulletin
Online ISSN : 1347-5215
Print ISSN : 0918-6158
ISSN-L : 0918-6158
Regular Articles
Acute Diphenyl Diselenide Treatment Reduces Hyperglycemia But Does Not Change Delta-Aminolevulinate Dehydratase Activity in Alloxan-Induced Diabetes in Rats
Nilda Berenice de Vargas BarbosaCaroline OliveiraDioneia AraldiVanderlei FolmerJoão Batista Teixeira RochaCristina Wayne Nogueira
Author information
JOURNAL FREE ACCESS

2008 Volume 31 Issue 12 Pages 2200-2204

Details
Abstract

This study was designed to evaluate the effect of diphenyl diselenide in a classical model of alloxan-induced diabetes in rats. Oxidative stress is involved in alloxan toxic effects and we have hypothesized that diphenyl diselenide via its antioxidant properties could confer protection against alloxan pancreatic toxicity. Diabetes was induced by administration of alloxan (150 mg/kg, intravenously). Diphenyl diselenide (10 mg/kg, subcutaneously) was administered for 6 d before (prevention group) or for 6 d after (remediation group) diabetes induction. Diphenyl diselenide treatment reduced the blood glucose and fructosamine levels, which were increased in alloxan-treated rats. However, the delta-aminolevulinate dehydratase (δ-ALA-D) activity inhibited by alloxan was not restored by diphenyl diselenide. Moreover, diphenyl diselenide caused by itself an inhibition in hepatic and renal δ-ALA-D activity. Our findings suggest that the acute treatment with diphenyl diselenide reduces the hyperglycemia but does not improve δ-ALA-D activity decreased by alloxan. Although the dose of diphenyl diselenide used here for treating diabetic animals has been relatively high and produced toxic effects, the compound or analogous molecules might not be rejected as a promising anti-hyperglycemic agent.

Content from these authors
© 2008 The Pharmaceutical Society of Japan
Previous article Next article
feedback
Top